Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

By afschroeder • July 11, 2026

Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le Bescond L, Lopez-Rios F, Mountzios G, Passaro A, Paz-Ares L, Pistilli B, Powles T, Reguart N, Remon J, Schmelzle T, Skynner MJ, Smit E, Smyth E, Swanton C, Van Cutsem E, Loi S, Stahel RA. Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation. ESMO Open. 2026 Jul 10;11(8):108316. doi: 10.1016/j.esmoop.2026.108316. Epub ahead of print. PMID: 42431135.

Tags: Antibody–drug conjugate, Biomarker, Hematology/Oncology, Publications, research priorities, resistance, solid tumours

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West[...]

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]